BS
CLDX icon

Boenning & Scattergood’s Celldex Therapeutics CLDX Stock Holding History

Boenning & Scattergood’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,997
Closed -$15K – 281
2018
Q4 		$15K Sell
4,997
-346
-6% -$1.7K 0.01% 262
2018
Q3 		$36K Buy
5,343
+50
+0.9% +$350 0.01% 270
2018
Q2 		$40K Buy
+5,293
New +$70.8K 0.01% 271

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boenning & Scattergood's CLDX Position: Q1 2019 in Review

Boenning & Scattergood sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 4,997 shares — an estimated $15K sold.

Boenning & Scattergood first reported a position in CLDX in Q2 2018 and held it in 3 quarters. The position peaked at $40K in Q2 2018. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Boenning & Scattergood reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Boenning & Scattergood sold 4,997 Celldex Therapeutics shares in Q1 2019, an estimated $15K.
  • Boenning & Scattergood first reported a position in Celldex Therapeutics in Q2 2018 and held it in 3 quarters.
  • Boenning & Scattergood's Celldex Therapeutics position peaked at $40K in Q2 2018.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Boenning & Scattergood's 13F filing for Q1 2019, filed 22 Apr 2019.